The US Food and Drug Administration (FDA) has approved the first electronic nebulizer to deliver cystic fibrosis patients their therapy. The agency approved PARI’s eRapid nebulizer system to deliver Genentech’s Pulmozyme (dornase alfa [recombinant human DNase] for treatment of cystic fibrosis (CF). According to PARI, eRapid cuts the average treatment …